Genome-wide CRISPR activation screens of neuroblastoma cells treated with ALK inhibitors brigatinib or ceritinib for 14 days identified Pim1 as a resistance gene, due to an anti-apoptotic phosphorylation of BAD by PIM1 [149]. The gene discussed is ALK; the disease is neuroblastoma.